A gradient-loadable 64Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography

Lee, Helen; Zheng, Jinzi; Gaddy, Daniel F.; Orcutt, Kelly Davis; Leonard, Shannon C.; Geretti, Elena; Hesterman, Jacob; Harwell, Catey; Hoppin, Jack; Jaffray, David A.; Wickham, Thomas J.; Hendriks, Bart S.; Kirpotin, Dmitri B.

doi:10.1016/j.nano.2014.08.011

Cited by 51 publications

(61 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies demonstrated that permeability rates depended on molecular or particle properties such as hydrodynamic diameter and shape (4). Liposomal imaging agents based on single-photon emission computed tomographic (SPECT) or positron emission tomographic (PET) imaging have been examined as well (20)(21)(22). A widely studied class of imaging agents is superparamagnetic iron oxide nanoparticles, which have excellent MRI contrast characteristics and demonstrate concentration-related negative contrast on T2-and T2 Ã -weighted sequences.…”

Section: Introductionmentioning

confidence: 99%

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

Ramanathan

Korn

Raghunand

et al. 2017

Clinical Cancer Research

Self Cite

153

View full text Add to dashboard Cite

Purpose: To determine whether deposition characteristics of ferumoxytol (FMX) iron nanoparticles in tumors, identified by quantitative MRI, may predict tumor lesion response to nanoliposomal irinotecan (nal-IRI).Experimental Design: Eligible patients with previously treated solid tumors had FMX-MRI scans before and following (1, 24, and 72 hours) FMX injection. After MRI acquisition, R2 Ã signal was used to calculate FMX levels in plasma, reference tissue, and tumor lesions by comparison with a phantom-based standard curve. Patients then received nal-IRI (70 mg/m 2 free base strength) biweekly until progression. Two percutaneous core biopsies were collected from selected tumor lesions 72 hours after FMX or nal-IRI.Results: Iron particle levels were quantified by FMX-MRI in plasma, reference tissues, and tumor lesions in 13 of 15 eligible patients. On the basis of a mechanistic pharmacokinetic model, tissue permeability to FMX correlated with early FMX-MRI signals at 1 and 24 hours, while FMX tissue binding contributed at 72 hours. Higher FMX levels (ranked relative to median value of multiple evaluable lesions from 9 patients) were significantly associated with reduction in lesion size by RECIST v1.1 at early time points (P < 0.001 at 1 hour and P < 0.003 at 24 hours FMX-MRI, one-way ANOVA). No association was observed with post-FMX levels at 72 hours. Irinotecan drug levels in lesions correlated with patient's time on treatment (Spearman r ¼ 0.7824; P ¼ 0.0016).Conclusions: Correlation between FMX levels in tumor lesions and nal-IRI activity suggests that lesion permeability to FMX and subsequent tumor uptake may be a useful noninvasive and predictive biomarker for nal-IRI response in patients with solid tumors.

show abstract

Section: Introductionmentioning

confidence: 99%

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

Ramanathan

Korn

Raghunand

et al. 2017

Clinical Cancer Research

Self Cite

153

View full text Add to dashboard Cite

show abstract

“…In vitro as well as in vivo stability studies exhibited high stability up to 48h (>99%) and 24h (>94%) respectively. PET/CT imaging in BT474-M3 xenografts substantiated the use of these radiolabeled nanoparticles as PET tracers for in vivo liposome tracking [11]. A more recent study utilized DOX-loaded liposomes capable of PET and NIFR imaging after conjugation with 64 Cu and IRDye800CW respectively.…”

Section: Copper-64mentioning

confidence: 87%

“…A strategy for labeling different nanoplatforms via covalent bonding with 11 C, in order to develop a useful tool for PET and MR imaging, was reported by Sharma et al (2013). In their study, they examined nanoparticles appropriately functionalized with amine (-NH2) and carboxylic acid (-COOH) groups and more precisely iron oxide nanoparticles (IONPs), and platinum and silicon dioxide nanoparticles.…”

Section: Carbon-11mentioning

confidence: 99%

Radiolabeled Nanoparticles in Nuclear Oncology

2018

View full text Add to dashboard Cite

A B S T R A C TDuring recent years, a plethora of pioneering radiolabeled nanoparticles have grown to be an integral part of nuclear medicine as theranostic tools. Herein, we focus on the most representative examples of nanoparticles of the past decade, which have been investigated in conjunction with radioisotopes aiming to serve as drug delivery or imaging agents. The present review highlights the key attributes of each nanosystem and the following classification of radiolabeled nanovehicles is based on increasing mass number (A) of radioisotopic elements.

show abstract

“…The company hypothesized that the degree of liposomal delivery to tumors may be predictive of response to MM-302. An imageable, 64 Cu-labeled version of MM-302 was created for this purpose [197], which has been introduced in the clinic through inclusion into NCT01304797. Eleven of the patients enrolled in the trial received 64 Cu-MM-302 for PET/CT imaging [198].…”

Section: Liposomal Companion Diagnosticsmentioning

confidence: 99%

Integration of imaging into clinical practice to assess the delivery and performance of macromolecular and nanotechnology-based oncology therapies

Spence

Souza

Dou

et al. 2015

Journal of Controlled Release

View full text Add to dashboard Cite

A gradient-loadable 64Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography

Cited by 51 publications

References 27 publications

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

Radiolabeled Nanoparticles in Nuclear Oncology

Integration of imaging into clinical practice to assess the delivery and performance of macromolecular and nanotechnology-based oncology therapies

Contact Info

Product

Resources

About